Get the Stockscreener App
8.15
6.32%
-0.55
Promis Neurosciences Inc stock is traded at $8.15, with a volume of 20,418.
It is down -6.32% in the last 24 hours and down -36.72% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
See More
Previous Close:
$8.70
Open:
$8.89
24h Volume:
20,418
Relative Volume:
0.75
Market Cap:
$73.09M
Revenue:
Net Income/Loss:
$-40.62M
P/E Ratio:
-0.4199
EPS:
-19.4076
Net Cash Flow:
$-35.63M
1W Performance:
-15.19%
1M Performance:
-36.72%
6M Performance:
-31.17%
1Y Performance:
-30.13%
1-Day Range:
$7.935
$9.64
1-Week Range:
$7.935
$9.78
52-Week Range:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
8.15 | 73.09M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Promis Neurosciences Inc Stock (PMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-26 | Initiated | Chardan Capital Markets | Buy |
Promis Neurosciences Inc Stock (PMN) Latest News
80,000 stock options go to Ivana Rubino at ProMIS Neurosciences (PMN), exercisable at $9.37. - Stock Titan
Alzheimer’s drug data are expected in Q1 2027. ProMIS hires a former Biogen leader to shape market plans. - Stock Titan
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - Carroll County Mirror-Democrat
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - kalkine.ca
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - Kalkine
ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Nigeria
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com India
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com UK
ProMIS Neurosciences (PMN) Edges Up 0.24% to $12.56 as Shares Consolidate Between Support and ResistanceChannel Breakout - siam.in
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Yahoo Finance
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Revenue Estimate Trend - vinanet.vn
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Positive Surprise Momentum - https://www.dars.gov.et/
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Book Value Growth - dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Profit Guidance Range - dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Earnings Forecast Report - www.dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Diluted EPS Report - dars.gov.et
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEPS Miss Report - dars.gov.et
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEPS Estimate Trend - dars.gov.et
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - vinanet.vn
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Call Wall - dars.gov.et
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Hedge Fund Favorites - dars.gov.et
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
Promis Neurosciences Q2 Earnings Call Highlights - TradingView
Promis Neurosciences Q2 Earnings Call Highlights - Yahoo Finance
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Promis Neurosciences Inc Stock (PMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kirwin Patrick D. | Director |
Apr 22 '26 |
Buy |
11.33 |
4,000 |
45,320 |
4,653 |
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):